Plus Therapeutics, Inc.
PSTV
Price:
$1.5399
Market Cap:
$9.08M
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Au...[Read more]
Industry
Biotechnology
IPO Date
2001-07-11
Stock Exchange
NASDAQ
Ticker
PSTV
The ROE as of September 2024 (TTM) for Plus Therapeutics, Inc. (PSTV) is 473.01%
According to Plus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 473.01%. This represents a change of 611.70% compared to the average of 66.46% of the last 4 quarters.
Plus Therapeutics, Inc. (PSTV) Historical ROE (quarterly & annually)
How has PSTV ROE performed in the past?
The mean historical ROE of Plus Therapeutics, Inc. over the last ten years is -98.98%. The current 473.01% ROE has changed -577.88% with respect to the historical average. Over the past ten years (40 quarters), PSTV's ROE was at its highest in in the September 2019 quarter at 328.75%. The ROE was at its lowest in in the March 2020 quarter at -1278.82%.
Average
-98.98%
Median
-187.59%
Minimum
-1098.45%
Maximum
987.83%
Plus Therapeutics, Inc. (PSTV) ROE by Quarter and Year
Discovering the peaks and valleys of Plus Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 354.28%
Maximum Annual ROE = 987.83%
Minimum Annual Increase = -405.53%
Minimum Annual ROE = -1098.45%
| Year | ROE | Change |
|---|---|---|
| 2023 | 987.83% | -405.53% |
| 2022 | -323.32% | 144.47% |
| 2021 | -132.25% | -57.12% |
| 2020 | -308.41% | -71.92% |
| 2019 | -1098.45% | 354.28% |
| 2018 | -241.80% | 38.56% |
| 2017 | -174.51% | -13.04% |
| 2016 | -200.67% | 30.68% |
| 2015 | -153.56% | -123.43% |
| 2014 | 655.35% | -178.41% |
Plus Therapeutics, Inc. (PSTV) Average ROE
How has PSTV ROE performed in the past?
The current ROE of Plus Therapeutics, Inc. (PSTV) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
177.42%
5-year avg
-174.92%
10-year avg
-98.98%
Plus Therapeutics, Inc. (PSTV) ROE vs. Peers
How is PSTV’s ROE compared to its peers?
Plus Therapeutics, Inc.’s ROE is greater than Aditxt, Inc. (-607.01%), greater than Palisade Bio, Inc. (-124.86%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Zura Bio Limited (-35.45%), greater than Altamira Therapeutics Ltd. (-233.96%), greater than Immix Biopharma, Inc. (-86.48%), greater than Enveric Biosciences, Inc. (-234.16%), greater than First Wave BioPharma, Inc. (-28.76%), greater than Dermata Therapeutics, Inc. (-197.44%), less than Panbela Therapeutics, Inc. (545.45%), less than ContraFect Corporation (403.13%), greater than Protara Therapeutics, Inc. (-55.03%), less than Vaccinex, Inc. (1.11%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Miromatrix Medical Inc. (-119.21%), greater than Surrozen, Inc. (-178.66%), greater than Avenue Therapeutics, Inc. (-749.10%), greater than Hoth Therapeutics, Inc. (-81.79%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Virax Biolabs Group Limited (-115.10%),
| Company | ROE | Market cap |
|---|---|---|
| -607.01% | $2.61M | |
| -124.86% | $4.72M | |
| -243.91% | $1.50M | |
| -112.11% | $2.51M | |
| -35.45% | $230.22M | |
| -233.96% | $1.66M | |
| -86.48% | $50.78M | |
| -234.16% | $4.46M | |
| -28.76% | $5.99M | |
| -197.44% | $2.79M | |
| 545.45% | $1.63M | |
| 403.13% | $1.72M | |
| -55.03% | $38.68M | |
| 1.11% | $9.76M | |
| -110.60% | $15.21M | |
| -119.21% | $92.95M | |
| -178.66% | $27.92M | |
| -749.10% | $3.91M | |
| -81.79% | $6.96M | |
| -154.04% | $30.52M | |
| -115.10% | $12.33M |
Build a custom stock screener for Plus Therapeutics, Inc. (PSTV) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Plus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Plus Therapeutics, Inc. (PSTV) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Plus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Plus Therapeutics, Inc.'s ROE?
How is the ROE calculated for Plus Therapeutics, Inc. (PSTV)?
What is the highest ROE for Plus Therapeutics, Inc. (PSTV)?
What is the 3-year average ROE for Plus Therapeutics, Inc. (PSTV)?
What is the 5-year average ROE for Plus Therapeutics, Inc. (PSTV)?
How does the current ROE for Plus Therapeutics, Inc. (PSTV) compare to its historical average?